Voyager Therapeutics (NASDAQ:VYGR) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Voyager Therapeutics and Adaptimmune Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Voyager Therapeutics | -60.61% | -66.46% | -17.92% |
| Adaptimmune Therapeutics | -3,858.14% | -44.94% | -33.70% |
Insider & Institutional Ownership
78.8% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are held by institutional investors. 23.9% of Voyager Therapeutics shares are held by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Voyager Therapeutics and Adaptimmune Therapeutics' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Voyager Therapeutics | $104.39 million | 2.01 | $-43,600,000.00 | ($1.21) | -4.61 |
| Adaptimmune Therapeutics | $1.12 million | 692.36 | $-137,160,000.00 | ($1.32) | -3.80 |
Voyager Therapeutics has higher revenue and earnings than Adaptimmune Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Voyager Therapeutics and Adaptimmune Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Voyager Therapeutics | 0 | 8 | 6 | 0 | 2.43 |
| Adaptimmune Therapeutics | 0 | 3 | 2 | 0 | 2.40 |
Voyager Therapeutics currently has a consensus target price of $12.9615, indicating a potential upside of 132.29%. Adaptimmune Therapeutics has a consensus target price of $15.50, indicating a potential upside of 209.38%. Given Adaptimmune Therapeutics' higher probable upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Voyager Therapeutics.
Risk and Volatility
Voyager Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.
Summary
Voyager Therapeutics beats Adaptimmune Therapeutics on 9 of the 14 factors compared between the two stocks.
